Journal article
Ahead of Print - Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis - Volume 25, Number 5—May 2019 - Emerging Infectious Diseases journal - CDC
Abstract
Bedaquiline is recommended by the World Health Organization for the treatment of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB). We pooled data from 5 cohorts of patients treated with bedaquiline in France, Georgia, Armenia, and South Africa and in a multicountry study. The rate of culture conversion to negative at 6 months (by the end of 6 months of treatment) was 78% (95% CI 73.5%-81.9%), and the treatment …
Authors
Mbuagbaw L; Guglielmetti L; Hewison C; Bakare N; Bastard M; Caumes E; Fréchet-Jachym M; Robert J; Veziris N; Khachatryan N
Journal
Emerging Infectious Diseases, Vol. 25, No. 5, pp. 936–943
Publisher
Centers for Disease Control and Prevention (CDC)
Publication Date
May 2019
DOI
10.3201/eid2505.181823
ISSN
1080-6040